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Commentary

The Centers for Disease Control and 
Prevention (CDC) supports health departments 
and community-based organizations to provide 
human immunodeficiency virus (HIV) counseling, 
testing, and referral (CTR) services. The goals of 
CTR, as defined by the 2001 Revised Guidelines 
for HIV Counseling, Testing, and Referral, are to 
ensure that HIV-infected persons and persons at 
increased risk for HIV infection (a) have access to 
HIV testing* to promote early knowledge of their 
HIV status; (b) receive high-quality HIV preven­
tion counseling to reduce their risk for transmitting 
or acquiring HIV; and (c) have access to appropri­
ate medical, preventive, and psychosocial support 
services [1, p.5]. 
The goals of CTR are reflected in CDC’s 2003 
Advancing HIV Prevention initiative, which 
emphasizes increasing the availability of, and 
access to, a range of critical HIV prevention 
services, such as routine testing and early identifi­
cation of new cases, partner notification, referral to 
services and counseling, and care and treatment for 
HIV-infected persons [2]. A CDC report of the 
research underlying the Advancing HIV Prevention 
initiative describes the importance of early detec­
tion of HIV infection [3]: 
There are many benefits to early knowledge of

HIV infection, including early entry into treatment to

prevent illnesses that arise from a weakened immune

system, treatment of other conditions like substance

abuse and sexually transmitted diseases, and access to

social services and medical treatments, when appropri­

ate. HIV-infected persons in care are now living longer

than before thanks to new highly effective treatments.

In addition to these personal benefits, knowledge of

one’s HIV infection can help prevent spread of the

infection to others. When people know that they are

infected with HIV, they are significantly more likely to

protect their partners from infection than when they

were unaware of their infection.

Since 1989, the HIV Counseling and Testing 
System (CTS) has been used to monitor CDC-
supported HIV counseling and testing services. 
Through this system, each CDC-supported HIV 
counseling and testing event is reported to CDC 
and includes information about demographics, 
self-reported behavior, and HIV test results. Data 
from this system are used to guide the develop­
ment of HIV prevention programs in response to 
the needs of various communities. 
HIV Counseling and Testing at CDC-
Supported Sites—United States, 1999–2004 
includes data about counseling and testing services 
that were supported with CDC funds during these 
years. Through cooperative agreements, the CDC 
funded 59 health departments to provide counsel­
ing and testing services†: the 50 state health depart­
ments, 6 municipal or county health departments 
(Chicago, Houston, Los Angeles, New York, 
Philadelphia, and San Francisco), and the health 
departments of the District of Columbia, Puerto 
Rico, and the U.S. Virgin Islands. Health depart­
ments receiving CDC funds for counseling and 
testing may provide services directly to persons 
or indirectly through contracts with local health 
departments or community-based organizations. 
Health departments may also provide tests or 
laboratory services to local health departments or 
community-based organizations. HIV Counseling 
and Testing at CDC-Supported Sites—United 
States, 1999–2004 does not include information 
about counseling and testing services that were not 
supported with CDC funds, such as HIV tests 
conducted in health maintenance organizations or 
blood donation facilities. 
CDC-supported counseling and testing services 
were provided at a variety of agency sites includ­
ing HIV counseling and testing centers, sexually 
transmitted disease (STD) clinics, family planning 
*HIV testing can be conducted by using a variety of different fluids (e.g., whole blood, serum, oral fluid) and a variety of test technologies that 
have been approved for diagnostic use by the Food and Drug Administration (FDA). Since September 2003, CDC has provided funds for 
rapid HIV testing, which provides the person being tested with test results in about 20 minutes. 
† American Samoa, Guam, Marshall Islands, Micronesia, Northern Mariana Islands, and Palau also received funds to provide counseling and 
testing services; however, because data collection in these areas was limited, this report does not include information on counseling and 
testing activities for these areas. 
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clinics, prenatal/obstetric and gynecological 
clinics, hospitals/private medical doctors’ offices, 
community health centers/public health clinics, 
prisons/jails, drug treatment centers, tuberculosis 
clinics, and field visit/outreach settings. Staff 
members at these sites collected information about 
the number of tests provided, the results of those 
tests, and information about the demographics and 
behavioral risk factors of the persons tested. This 
information was then reported to their health 
department, which was required to report these 
data quarterly to CDC. 
Health departments submitted either test-level 
or aggregate-level (summary) data (see Table 1 for 
a list of the health departments and their reporting 
methods). Table 2 shows data for health depart­
ments that submit aggregate-level data, as well as 
totals for aggregate-level, test-level, and all 
CDC-supported tests. Tables 3–9 show data 
for health departments that submit test-level data; 
these test-level data account for approximately 
90% of all CDC-supported HIV tests from 1999 
through 2004. 
The data presented in the tables and figures of 
this report represent the number of HIV tests 
conducted in a particular year rather than the 
number of individuals tested. For example, a 
person who was tested twice in 1 year would be 
counted twice in the data. Because these data 
represent neither individuals nor the general 
population, data may not represent changes in the 
prevalence or incidence of HIV infection in the 
U.S. population.
Estimates of the total number of persons 
infected with HIV are available through applying 
HIV prevalence estimation techniques to CDC 
HIV/AIDS surveillance data [4]. HIV testing 
estimates for the general population are available 
from household-based sample surveys, such as the 
2002 Behavioral Risk Factor Surveillance System 
(BRFSS) [5]. Comparability of the data from 
surveillance reports, BRFSS, and this report is 
limited by differences in data collection and 
estimation techniques. The limitations and compa­
rability of the data from this report are described in 
the Technical Notes. The reader is encouraged to 
review that section before drawing inferences from 
the data. 
Highlights of Analysis* 
Total HIV Tests and HIV-Positive Results 
From 1999 through 2004, the reported number 
of HIV tests remained relatively stable at approxi­
mately 1.9 million tests per year (Table 3). The 
largest number of tests with HIV-positive results 
(28,810) occurred in 2001, and the smallest num­
ber of tests with HIV-positive results (25,096) 
occurred in 2004. The rate of positive test results† 
decreased from 1.5% in 1999 to 1.3% in 2004. 
Age Group 
From 1999 through 2004, the largest number of 
HIV tests was conducted for persons in the age 
groups 19–24 and 25–34 years; however, the 
largest number of HIV-positive test results was 
found for the age group 35–44 years (Table 3). For 
example, in 2004, although the age groups 19–24 
and 25–34 years accounted for 29% and 28% of all 
HIV tests, respectively, the age group 35–44 years 
accounted for 34% of all HIV-positive test results 
(Figure 1). The number of HIV tests was higher 
in 2004 than in 1999 for those in the age groups 
19–24, 45–54, 55–64, and 65 years and older, 
whereas the number of HIV tests was lower in 
2004 than in 1999 for those in the age groups 
younger than 13, 13–18, 25–34, and 35–44 years 
(Table 3). 
Race/Ethnicity 
From 1999 through 2004, the number of HIV 
tests consistently declined among whites (Table 3). 
Whites accounted for 43% of all HIV tests in 1999 
and 36% in 2004 (Figure 2). During this period, 
the number of HIV tests increased for blacks. In 
1999, blacks accounted for 34% of all HIV tests; 
by 2004, they surpassed whites and accounted for 
* Note that the results reported in this section reflect only data from health departments that use test-level reporting (see Table 1 and 
Technical Notes for additional details). 
† The rate of positive test results is calculated by dividing the total number of positive test results by the total number of tests in a given 
calendar year. 
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39% of all HIV tests. From 1999 through 2004, 
blacks accounted for more than 50% of HIV-
positive test results (Figure 3). For each of these 
years, the number of HIV-positive test results for 
blacks was more than twice that for whites or 
Hispanics (Table 3). 
Sex 
From 1999 through 2004, the number of HIV 
tests reported for females exceeded those reported 
for males by approximately 6% (Table 3). For each 
of these years, the reported number of test results 
that were HIV-positive for males was more than 
double that for females. 
Sex and Age Group 
In 2004, the proportion of HIV tests reported 
for females (vs. males) increased through the age 
group 13–18 years and then steadily declined 
(Figure 4). In 2004, for persons 19 years and older, 
males accounted for approximately 71% of test 
results that were HIV-positive (Figure 5). 
Race/Ethnicity, Sex, and Age Group 
From 1999 through 2004, the number of HIV 
tests among males and females in the white, black, 
and Hispanic racial/ethnic groups was highest 
among the age groups 19–24 and 25–34 years, 
with the exception of black males in 1999 (when 
more tests were given to 35- to 44-year-olds than 
to 19- to 24-year-olds; Table 4). In the age groups 
19–24 and 25–34 years, for both men and women, 
the percentage of HIV test results that were posi­
tive was higher for blacks and Hispanics than for 
whites (Table 4). However, during this period, the 
percentage of HIV test results that were positive 
declined for black and Hispanic females aged 19– 
24 and 25–34, and for black and Hispanic males 
aged 25–34. From 1999 through 2004, the percent­
age of test results that were positive was higher for 
black adolescent and adult females (13 years of 
age and older) than for white females in the same 
age group. 
In 2004, among males in every age group, the 
rate of positive test results for blacks and Hispan­
ics was higher than that for whites (Figure 6). For 
males 25 and older, the rate of positive test results 
for blacks was similar to that of Hispanics. In 
2004, among black and Hispanic males in the age 
groups 35-44 and 45-54 years, more than 3% of 
the HIV test results were positive. In 2004, among 
females in every age group, the rate of positive test 
results for blacks was higher than that for both 
whites and Hispanics (Figure 7). 
Risk Category 
Between 1999 and 2004, the number of HIV 
tests increased by 24% among persons reporting 
male-to-male sexual contact* (Table 3). Among 
those reporting male-to-male sexual contact, 
the percentage of HIV tests that were positive 
declined from 5.6% in 1999 to 5.3% in 2004 
(Figure 8). Testing among those reporting 
male-to-male sexual contact and injection drug use 
accounted for a relatively small percentage of 
overall testing (approximately .6%), but this group 
had the highest rate of positive test results, averag­
ing 6.9% for the 6-year period. The largest number 
of HIV tests was administered to those reporting 
heterosexual contact.† The rate of positive test 
results for this risk group remained below 1% from 
1999 through 2004. 
Risk Category and Race/Ethnicity 
From 1999 through 2004, the rate of positive 
HIV test results was more than twice as high for 
blacks who reported male-to-male sexual contact 
than for whites who reported the same risk factor 
(Table 5). The rate of positive test results for 
Hispanics who reported male-to-male sexual 
contact fell between that of blacks and whites for 
all 6 years. In 2004, among those who reported 
male-to-male sexual contact, the percentage of 
HIV test results that were positive was 10.1% for 
blacks, 5.7% for Hispanics, and 3.6% for whites. 
From 1999 through 2004, among those who 
* This risk category (“male-to-male sexual contact”) excludes persons who reported both male-to-male sexual contact and injection drug use. 
† This risk category (“heterosexual contact”) excludes persons who reported injection drug use. 
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reported heterosexual contact, blacks had the 
highest rate of positive test results (range 1.2% to 
1.7%) compared with Hispanics (range 0.7% to 
0.9%) and whites (0.3% for all years). 
Test Site and Test Type 
For each year from 1999 through 2004, free-
standing HIV counseling and testing centers and 
STD clinics reported the highest number of HIV 
tests and positive test results (Table 6; Figure 9). 
In 2004, the rate of positive results was 1.8% at 
HIV counseling and testing centers and 1% at STD 
clinics. That same year, the rate of positive results 
was highest in community health centers/public 
health clinics (2.4%), hospitals/private medical 
doctors’ offices (2.2%), field visit settings (1.8%), 
and HIV counseling and testing centers (1.8%). 
Between 1999 and 2004, testing in prisons/jails 
increased by 28% and testing in field visit settings 
more than doubled. Over those same years, testing 
declined by 17% in HIV counseling and testing 
centers, and by 41% in prenatal/obstetric and 
gynecological clinics. Between 1999 and 2004, the 
number of confidential tests increased by 13%, 
whereas the number of anonymous tests decreased 
by 37%. 
Receipt of Test Results 
In 2004, persons tested received their HIV test 
results for 78% of tests (Table 7). From 1999 
through 2004, blacks were less likely than mem-
bers of other racial/ethnic groups to receive their 
results. In 2004, 71% of test results were received 
by blacks, compared with 82% for whites, 81% for 
Hispanics, 83% for Asians/Pacific Islanders, and 
78% for American Indians/Alaska Natives. From 
1999 through 2004, males were more likely than 
females to receive their test results. Overall, in 
2004, persons tested were more likely to receive 
their test results if the results were positive 
(84%) than if they were negative (78%). For 
every racial/ethnic group except Asians/Pacific 
Islanders, the percentage of positive test results 
received increased between 2003 and 2004 
(Table 8). For example, the percentage of positive 
test results received by blacks increased from 
79% in 2003 to 82% in 2004; for Hispanics, the 
same percentages increased from 83% to 86%.
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Table 1.  Use of test- or aggregate-level reporting and type of counseling and testing reporting system, by health department, 1999–2004 
Test-level reporting Test-level reporting 
CDC scan system Health department-specific systems Aggregate-level reporting 
Arizona California Alabama 
Chicago Colorado Alaska 
Connecticut Florida Arkansas 
Delaware Houston Hawaii 
District of Columbia Indiana Iowa 
Georgia Los Angeles Kansas 
Idaho Louisiana King County, Washington 
Illinois Maine (since 2000) New Hampshire 
Kentucky Maryland South Dakota 
Missouri Massachusetts West Virginia 
Nebraska Michigan 
Nevada Minnesota 
New Jersey Mississippi 
New York City Montana 
North Carolina New Mexico 
North Dakota (since 2003) New York 
Ohio Oregon 
Oklahoma San Francisco 
Pennsylvania South Carolina 
Philadelphia Tennessee 
Puerto Rico Texas 
Rhode Island Virginia 
U.S. Virgin Islands 
Utah 
Vermont 
Washington 
Wisconsin 
Wyoming 
Note. Names of municipalities are incorporated in the alphabetical listing. 
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Table 2.   Aggregate-level data on HIV tests and HIV-positive results, by health department, 1999–2004 
       HIV tests HIV-positive results 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Alabamaa  100,892 a   110,102 103,160 109,776   114,701  684 (0.7)  a 935 (0.8)  709 (0.7)  638 (0.6) 772 (0.7) 
Alaska 4,796  6,083  6,079  6,204  5,591 3,651  9 (0.2) 12 (0.2) 13 (0.2)  10 (0.2)  12 (0.2)  — 
Arkansas  80,888  80,865  76,843  83,696  75,697  67,570  328 (0.4) 316 (0.4) 155 (0.2)  273 (0.3)  277 (0.4)  295 (0.4) 
Hawaii  9,627  8,702  8,189  8,551  8,360  8,412  31 (0.3) 34 (0.4) 42 (0.5)  51 (0.6)  40 (0.5)  26 (0.3) 
Iowa  12,255  12,267  10,608  9,844  10,710  10,702  44 (0.3) 37 (0.3) 37 (0.4)  42 (0.4)  43 (0.4)  56 (0.5) 
Kansas 12,496  12,292     11,465     11,423     11,075  15,155   28 (0.2) 33  (0.3) 28 (0.2)       38 (0.3)       41 (0.4)  73 (0.5) 
King County, Washington  31,685  29,313  28,310  28,159  27,435  28,853  257 (0.8) 259 (0.9) 231 (0.8)  264 (0.9)  317 (1.2)  276 (1.0) 
Maineb  2,285 b b b b  b  7 (0.3)  b  b  b  b  b 
New Hampshire  3,284  3,103  3,259  2,926 2,914  3,356  15 (0.5) 14 (0.5) 20 (0.6)  29 (1.0)  8 (0.3)  26 (0.8) 
North Dakotac  3,094  2,156  1,942  2,160 c c 18 (0.6)  —  —  7 (0.3)  c  c 
South Dakota  1,406  1,195  4,157  4,903  4,898  5,173  7 (0.5) 8 (0.7) 19 (0.5)  17 (0.3)  9 (0.2)  –– 
West Virginia  5,897  5,412  5,492  5,554  5,078  5,098  16 (0.3) 31 (0.6) 30 (0.5)  33 (0.6)  40 (0.8)  39 (0.8) 
Aggregate-level total 268,605 161,388 266,446 266,580 261,534 262,671 1,444 (0.5) 744 (0.5) 1,510  (0.6) 1,473 (0.6) 1,425 (0.5) 1,563 (0.6) 
Test-level total 1,869,519 1,905,051 1,962,061 1,946,021 1,867,892 1,892,734 27,535 (1.5) 27,067  (1.4) 28,810 (1.5) 28,439 (1.5) 26,984 (1.4) 25,096 (1.3) 
Total CDC-supported 2,138,124 2,066,439 2,228,507 2,212,601 2,129,426 2,155,405 28,979 (1.4) 27,811  (1.3) 30,320 (1.4) 29,912 (1.4) 28,409 (1.3) 26,659 (1.2) 
Note. To protect confidentiality, minor adjustments have been made to some of the cells.

Dash indicates data not shown because of small cell count.

a Did not report data in 2000.

b Began reporting test-level data in 2000.

c Began reporting test-level data in 2003.
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Table 3.  Reported HIV tests and HIV-positive results, by characteristics of persons tested, 1999–2004
       HIV tests HIV-positive results 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Age at test (yrs) 
<5 4,490 4,245 2,281 1,692 1,327 1,144 103 (2.3) 74 (1.7) 49 (2.1) 41 (2.4) 32 (2.4) 30 (2.6)
 5–12 4,167 3,348 3,306 2,834 2,230 2,215 31 (0.7) 31 (0.9) 20 (0.6) 19 (0.7) 20 (0.9) 16 (0.7) 
13–18 228,160 221,092 215,656 206,743 189,964 190,791 496 (0.2) 502 (0.2) 485 (0.2) 478 (0.2) 493 (0.3) 454 (0.2) 
19–24 514,922 529,900 548,987 548,109 527,908 544,765 2,898 (0.6) 2,947 (0.6) 3,093 (0.6) 3,183 (0.6) 3,175 (0.6) 3,205 (0.6) 
25–34 538,044 536,682 546,164 541,040 523,182 530,509 9,358 (1.7) 8,659 (1.6) 8,644 (1.6) 8,044 (1.5) 7,745 (1.5) 7,097 (1.3) 
35–44 362,647 374,250 383,742 375,445 357,510 352,890 9,824 (2.7) 9,664 (2.6) 10,522 (2.7) 10,472 (2.8) 9,556 (2.7) 8,498 (2.4) 
45–54 141,071 154,013 167,313 173,425 175,146 183,374 3,557 (2.5) 3,754 (2.4) 4,314 (2.6) 4,539 (2.6) 4,439 (2.5) 4,376 (2.4) 
55–64 36,267 39,506 43,269 45,870 46,689 49,684 663 (1.8) 710 (1.8) 864 (2.0) 932 (2.0) 895 (1.9) 955 (1.9) 
≥65 12,722 13,248 15,522 15,324 14,577 14,286 161 (1.3) 150 (1.1) 223 (1.4) 195 (1.3) 188 (1.3) 153 (1.1) 
Not reporteda 27,029 28,767 35,821 35,539 29,359 23,076 444 (1.6) 576 (2.0) 596 (1.7) 536 (1.5) 441 (1.5) 312 (1.4) 
Race/ethnicity 
White, not Hispanic 803,432 771,686 750,317 732,050 687,988 687,649 6,265 (0.8) 5,875 (0.8) 6,270 (0.8) 6,356 (0.9) 6,100 (0.9) 5,835 (0.8) 
Black, not Hispanic 641,580 677,469 715,401 697,064 686,336 735,115 14,740 (2.3) 14,303 (2.1) 15,273 (2.1) 14,818 (2.1) 13,721 (2.0) 12,877 (1.8) 
Hispanic 338,111 370,979 400,789 421,462 397,617 372,239 5,531 (1.6) 5,840 (1.6) 6,122 (1.5) 6,192 (1.5) 5,900 (1.5) 4,999 (1.3) 
Asian/Pacific Islander 30,318 30,014 31,159 32,349 31,298 31,237 186 (0.6) 210 (0.7) 222 (0.7) 230 (0.7) 267 (0.9) 233 (0.7) 
American Indian/Alaska Native 12,075 11,880 12,245 11,934 12,039 11,205 138 (1.1) 125 (1.1) 124 (1.0) 122 (1.0) 148 (1.2) 124 (1.1) 
Other 23,787 25,169 28,841 29,731 32,269 34,596 320 (1.3) 325 (1.3) 341 (1.2) 404 (1.4) 514 (1.6) 639 (1.8) 
Not reporteda 20,216 17,854 23,309 21,431 20,345 20,693 355 (1.8) 389 (2.2) 458 (2.0) 317 (1.5) 334 (1.6) 389 (1.9) 
Sex 
Male 871,545 910,604 950,274 944,762 909,341 932,579 18,561 (2.1) 18,098 (2.0) 19,771 (2.1) 19,545 (2.1) 18,741 (2.1) 17,662 (1.9) 
Female 987,586 979,789 998,421 989,736 942,743 947,369 8,709 (0.9) 8,505 (0.9) 8,764 (0.9) 8,709 (0.9) 7,989 (0.8) 7,216 (0.8) 
Not reporteda 10,388 14,658 13,366 11,523 15,808 12,786 265 (2.6) 464 (3.2) 275 (2.1) 185 (1.6) 254 (1.6) 218 (1.7) 
Risk category 
Male-to-male sexual contact 11,518 11,839 11,472 11,827 12,119 10,319 854 (7.4) 825 (7.0) 806 (7.0) 747 (6.3) 818 (6.7) 697 (6.8)
 and injection drug use 
Male-to-male sexual contact 128,971 134,169 147,908 155,492 155,511 159,663 7,241 (5.6) 7,122 (5.3) 7,982 (5.4) 8,259 (5.3) 8,480 (5.5) 8,413 (5.3) 
Injection drug use 139,799 144,894 142,063 136,152 131,844 124,537 4,477 (3.2) 4,163 (2.9) 4,411 (3.1) 3,916 (2.9) 3,361 (2.5) 2,755 (2.2) 
Heterosexual contactb 1,376,856 1,397,986 1,390,587 1,396,188 1,333,292 1,382,771 12,751 (0.9) 12,705 (0.9) 13,164 (0.9) 12,753 (0.9) 11,939 (0.9) 11,332 (0.8) 
Otherc 212,375 216,163 270,031 246,362 235,126 215,444 2,212 (1.0) 2,252 (1.0) 2,447 (0.9) 2,764 (1.1) 2,386 (1.0) 1,899 (0.9) 
Total 1,869,519 1,905,051 1,962,061 1,946,021 1,867,892 1,892,734 27,535 (1.5) 27,067 (1.4) 28,810 (1.5) 28,439 (1.5) 26,984 (1.4) 25,096 (1.3) 
Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

a Includes records without a value for this variable. 
b Includes persons who had sex with partner at risk, who had a diagnosis of a sexually transmitted disease, who exchanged sex for drugs or money, who had sex while using noninjection drugs, who 
were victims of sexual assault, or whose only risk factor was heterosexual contact. 
c Includes persons who did not report a risk factor, whose record contained no data on risk factors, or who reported other risk factors (i.e., perinatal exposure, hemophilia, receipt of blood 
transfusion, or health care exposure). 
Table 4.  Reported HIV tests and HIV-positive results, by race/ethnicity, sex, and age group of persons tested, 1999–2004
       HIV tests HIV-positive results 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
White, not Hispanic 
Male 
<13 1,031 830 671 536 431 407 10 (1.0) 6 (0.7) —  —  —  — 
13–18  29,327  27,722  26,276  24,526  21,779  21,013 37 (0.1) 37 (0.1) 33 (0.1)  35 (0.1)  34 (0.2) 30 (0.1) 
19–24        90,911  91,001  91,027  90,670  86,260  89,838 435 (0.5) 358 (0.4) 470 (0.5)  437 (0.5)  471 (0.5) 468 (0.5) 
25–34  109,487  104,559  101,364  98,671  95,478  97,255 1,849 (1.7) 1,613 (1.5) 1,616 (1.6)  1,497  (1.5)  1,501  (1.6) 1,409 (1.4) 
35–44  87,964  86,273  83,270  79,956  75,054  74,543 1,779 (2.0) 1,699 (2.0) 1,885 (2.3)  1,986   (2.5)  1,830  (2.4) 1,769 (2.4) 
45–54  40,657  41,942  42,125  42,452  41,748  42,928 561 (1.4) 558 (1.3) 618 (1.5)  724 (1.7)  693 (1.7) 701 (1.6) 
≥55  16,449  16,955  17,300  17,532  17,363  18,574 134 (0.8) 148 (0.9) 204 (1.2)  168 (1.0) 184  (1.1) 206 (1.1) 
Not reporteda  4,565  5,077  9,454  10,172  8,188  5,312 73 (1.6) 56 (1.1) 159 (1.7)  171 (1.7)  139 (1.7) 60 (1.1) 
Female 
<13  1,287  1,042 826  608  593  502 6 (0.5) —  —  —  —  — 
13–18  73,499  64,963  59,612  56,286  49,778  46,972 54 (0.1) 53 (0.1) 48 (0.1)  46 (0.1)  36 (0.1)  28 (0.1) 
19–24  132,426  125,488  122,106  120,643      112,906      114,051 205 (0.2) 208 (0.2) 181 (0.1)  179 (0.1)        159 (0.1)  142 (0.1) 
25–34  105,015  97,040  92,021  89,382  83,943  84,817 436 (0.4) 415 (0.4) 428 (0.5)  387 (0.4)  356 (0.4)  370 (0.4) 
35–44  68,504  64,585  61,267  58,716  53,383  51,389 459 (0.7) 447 (0.7) 397 (0.6)  450 (0.8)  451 (0.8)  360 (0.7) 
45–54  26,231  26,243  26,341  26,014  24,813  25,474 128 (0.5) 166 (0.6) 152 (0.6)  178 (0.7)  168 (0.7)  201 (0.8) 
≥55  7,280  7,282  7,548  7,432  7,056  7,325 21 (0.3) 24 (0.3) 26 (0.3)  38 (0.5)  32 (0.5)  47 (0.6) 
Not reporteda  5,685  7,159  6,693  6,215  5,308  4,010 30 (0.5) 23 (0.3) 26 (0.4)  25 (0.4)  12 (0.2)  13 (0.3) 
Black, not Hispanic 
Male 
<13  1,341  1,088  864 698  565  637          42 (3.1) 26 (2.4) 11 (1.3)  13 (1.9)  8 (1.4)          11  (1.7) 
13–18  25,883  27,853  27,966  27,241  26,021  29,357          99 (0.4) 115 (0.4) 128 (0.5)  141 (0.5)  176 (0.7)  188 (0.6) 
19–24  71,056  78,546  84,752  82,867  80,917  91,084        841 (1.2) 879 (1.1) 996 (1.2)  1,012 (1.2)  1,073  (1.3)  1,257 (1.4) 
25–34  85,707  89,182  92,015  86,765  83,895  91,448  2,713  (3.2) 2,397 (2.7) 2,370 (2.6)     2,200  (2.5)  2,064  (2.5)  2,034 (2.2) 
35–44  73,430  78,536  83,217  77,954  74,772  77,392  3,420  (4.7) 3,341 (4.3) 3,728 (4.5)     3,475  (4.5)  3,021  (4.0)  2,685 (3.5) 
45–54  31,129  35,655  40,974  41,566  43,603  47,971  1,540  (4.9) 1,593 (4.5) 1,782 (4.3)     1,802  (4.3)  1,742  (4.0)  1,636 (3.4) 
≥55  10,164        11,179  12,970  13,091  13,647  15,413        332 (3.3) 371 (3.3) 457 (3.5)  458 (3.5)  416 (3.0)  406 (2.6) 
Not reporteda  3,405  3,138  3,276  3,137  2,496  2,645          83 (2.4) 101 (3.2) 119 (3.6)        104 (3.3)  87 (3.5)  100 (3.8) 
Female 
<13  1,591  1,360          1,116  966  782  809          35 (2.2) 20 (1.5) 14 (1.3)  16 (1.7)  15 (1.9)  20 (2.5) 
13–18  52,304  53,040  53,347  50,959    48,115  51,018        205 (0.4) 183 (0.3) 172 (0.3)  138 (0.3)  149 (0.3)  123 (0.2) 
19–24  99,531  105,236      112,947      113,130 112,829  120,379        714 (0.7) 720 (0.7) 662 (0.6)  677 (0.6)  636 (0.6)  544 (0.5) 
25–34  95,941  94,681  97,309  94,831  93,574  97,805  1,881  (2.0) 1,741 (1.8) 1,749 (1.8)     1,585  (1.7)  1,458  (1.6)  1,179 (1.2) 
35–44  61,560  64,959  68,736  66,223  63,939  64,956  1,934  (3.1) 1,888 (2.9) 2,017 (2.9)     2,039  (3.1)  1,737  (2.7)  1,542 (2.4) 
45–54  17,946  20,783  24,533  25,878  27,791  30,972        616 (3.4) 652 (3.1) 810 (3.3)  866 (3.3)  835 (3.0)  849 (2.7) 
≥55  4,661  5,283  6,166  6,555  6,992  7,925        124 (2.7) 127 (2.4) 150 (2.4)        187 (2.9)  176 (2.5)  189 (2.4) 
Not reporteda  3,814  4,133  3,221  3,089  2,867  2,660          79 (2.1) 61 (1.5) 67 (2.1)  53 (1.7)  40 (1.4)  48 (1.8) 
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Table 4.  Reported HIV tests and HIV-positive results, by race/ethnicity, sex, and age group of persons tested, 1999–2004 (continued)
1999 
No. 
2000 
No. 
       HIV tests 
2001 
No. 
2002 
No. 
HIV-positive results 
2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Male 
Hispanic 
<13  1,041  978  638  615  441  373            9 (0.9)  23 (2.4)  17 (2.7)  12 (2.0)  12 (2.7) — 
13–18  14,490  15,527  15,797  16,244  14,348  13,817          33 (0.2)  54 (0.3)  50 (0.3)  60 (0.4)  43 (0.3)  38 (0.3) 
19–24  39,477  45,412  49,044  51,689 48,803  46,141        400 (1.0)  461 (1.0)  483 (1.0)  523 (1.0)  492 (1.0)  496 (1.1) 
25–34  49,605  57,258  61,635  65,788  63,226  59,186  1,510  (3.0)  1,551  (2.7)  1,563  (2.5)  1,549  (2.4)  1,512  (2.4)  1,295 (2.2) 
35–44  28,198  33,759  36,629  39,240  38,203  35,465  1,390  (4.9)  1,484  (4.4)  1,578  (4.3)  1,612  (4.1)  1,540  (4.0)  1,279 (3.6) 
45–54  10,787  13,169  14,641  16,504 16,070  15,160        440 (4.1)  495 (3.8)  572 (3.9)  600 (3.6)  591 (3.7)  494 (3.3) 
≥55  4,943  5,879  7,046  7,997  7,590  6,647  130 (2.6)        118 (2.0) 157 (2.2)  175 (2.2)  165 (2.2)  140 (2.1) 
Not reporteda  2,603  1,453  3,514  3,458  2,319  1,989          49 (1.9)  46 (3.2)  86 (2.4)  77 (2.2)  79 (3.4)  26 (1.3) 
Female 
<13  1,079  1,029  652  635  507  404          19 (1.8)  17 (1.7)  16 (2.5)  10 (1.6)  7 (1.4) — 
13–18  22,746  23,052  23,157  22,305  20,707  19,848          49 (0.2)  43 (0.2)  32 (0.1)  43 (0.2)  30 (0.1)  18 (0.1) 
19–24  55,852  58,422  61,214  61,433 57,664  54,647        172 (0.3)  191 (0.3)  177 (0.3)  208 (0.3)  168 (0.3)  131 (0.2) 
25–34  62,631  65,160  70,235  74,022 70,009  66,790        555 (0.9)  543 (0.8)  496 (0.7)  437 (0.6)  415 (0.6)  354 (0.5) 
35–44  28,132  31,071  33,933  36,500 33,848  30,966        514 (1.8)  528 (1.7)  538 (1.6)  543 (1.5)  512 (1.5)  384 (1.2) 
45–54  8,796  10,401        11,959  13,781  13,130  12,140        160 (1.8)  167 (1.6)        231 (1.9)  219 (1.6)  207 (1.6)  217 (1.8) 
≥55  3,356  3,949  4,932  5,696  5,530  4,735          53 (1.6)  47 (1.2)  58 (1.2)  54 (0.9)  56 (1.0)  63 (1.3) 
Not reporteda  2,747  2,154  3,354  3,170  2,330  1,827          19 (0.7)  14 (0.6)  14 (0.4)  16 (0.5)  12 (0.5)  10 (0.5) 
1
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Total  1,776,264   1,811,486  1,859,690  1,843,838   1,761,611  1,787,016 26,377 (1.5) 25,808 (1.4) 27,543 (1.5) 27,225 (1.5)  25,540  (1.4)  23,560  (1.3) 
Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

Because of relatively small cell counts for Asian/Pacific Islander, American Indian/Alaska Native, other race/ethnicity, and not reported, only the data for white, not Hispanic; black, not Hispanic; and

Hispanic are shown.

Totals in this table may not match totals in other tables because of missing data on the "sex" variable.

Dash indicates data not shown because of small cell count.

a Includes records without a value for this variable. 
Table 5.  Reported HIV tests and HIV-positive results, by race/ethnicity and risk category of persons tested, 1999–2004
       HIV tests HIV-positive results 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
White, not Hispanic 
Male-to-male sexual contact 6,921 6,852 6,541 5,955 6,123 5,973 404 (5.8) 352 (5.1) 378 (5.8) 319 (5.4) 380 (6.2) 342 (5.7)
 and injection drug use 
Male-to-male sexual contact  78,858  80,258  84,290  86,443  84,218  85,875  2,998 (3.8)  2,801 (3.5)  3,175 (3.8)   3,189 (3.7)  3,154 (3.7)  3,096 (3.6) 
Injection drug use  79,200  79,838  73,925  74,077  71,835  70,174  913 (1.2)  809 (1.0)  797 (1.1)      811 (1.1)  706 (1.0)  648 (0.9) 
Heterosexual contacta  552,288  523,420  490,180  482,591  448,409  458,380  1,553 (0.3)  1,525 (0.3)  1,498 (0.3)  1,502 (0.3)  1,456 (0.3)  1,481 (0.3) 
Otherb  86,165  81,318  95,381  82,984  77,403  67,247  397 (0.5)  388 (0.5)  422 (0.4)  535 (0.6)  404 (0.5)  268 (0.4) 
Black, not Hispanic 
Male-to-male sexual contact 2,084  2,236  2,270  3,230  3,482  2,031      252 (12.1)      260 (11.6)      241 (10.6)  257 (8.0)  248 (7.1)  176 (8.7)
 and injection drug use 
Male-to-male sexual contact  20,233  21,450  25,013  25,624  26,885  30,177   2,474 (12.2)   2,486 (11.6)   2,771 (11.1)  2,799 (10.9)   2,865 (10.7)   3,051 (10.1) 
Injection drug use  29,197  29,416  31,703  27,263  26,841  25,290  2,232 (7.6)  1,902 (6.5)  2,072 (6.5)  1,680 (6.2)  1,402 (5.2)  1,155 (4.6) 
Heterosexual contacta  514,089  541,959  546,252  542,570  533,248  581,443  8,488 (1.7)  8,450 (1.6)  8,716 (1.6)  8,375 (1.5)  7,725 (1.4)  7,253 (1.2) 
Otherb  75,977  82,408   110,163  98,377  95,880  96,174  1,299 (1.7)  1,206 (1.5)  1,481 (1.3)  1,715 (1.7)  1,486 (1.5)  1,242 (1.3) 
Hispanic 
Male-to-male sexual contact 1,946  2,238  2,147  2,100  1,909  1,696  160 (8.2)  186 (8.3)  163 (7.6)  137 (6.5)  162 (8.5)  127 (7.5)
 and injection drug use 
Male-to-male sexual contact  22,777  24,990  29,628  32,976  33,327  31,637  1,473 (6.5)  1,553 (6.2)  1,727 (5.8)   1,919 (5.8)  2,007 (6.0)  1,800 (5.7) 
Injection drug use  26,144  30,470  31,162  29,188  27,213  23,251  1,243 (4.8)  1,372 (4.5)  1,455 (4.7)  1,323 (4.5) 1,121 (4.1)  801 (3.4) 
Heterosexual contacta  252,398  276,287  292,427  306,974  287,642  276,453  2,374 (0.9)  2,404 (0.9)  2,473 (0.8)  2,436 (0.8)  2,259 (0.8)  2,040 (0.7) 
Otherb  34,846  36,994  45,425  50,224  47,526  39,202  281 (0.8)  325 (0.9)  304 (0.7)  377 (0.8)  351 (0.7)  231 (0.6) 
Asian/Pacific Islander 
Male-to-male sexual contact  81 78 100 73  99 76          9 (11.1)          8 (10.3)  —  —  —      11 (14.5)
 and injection drug use 
Male-to-male sexual contact  3,281  3,624  4,246  5,165  5,450  5,742  92 (2.8)  101 (2.8)    111 (2.6)  134 (2.6)  170 (3.1)  144 (2.5) 
Injection drug use  528  595  738  558  645          611  —  8 (1.3)  9 (1.2)  10 (1.8)  6 (0.9)  9 (1.5) 
Heterosexual contacta  22,790  22,084  21,592  22,262  21,256  21,487  69 (0.3)  68 (0.3)  84 (0.4)  62 (0.3)        60 (0.3)  57 (0.3) 
Otherb  3,638  3,633  4,483  4,291  3,848  3,321        11 (0.3)  25 (0.7)  14 (0.3)  19 (0.4)  26 (0.7)  12 (0.4) 
American Indian/Alaska Native 
Male-to-male sexual contact 180  164  153  190  195  212        11 (6.1)        11 (6.7) 8 (5.2)  13 (6.8)  7 (3.6)  7 (3.3)
 and injection drug use 
Male-to-male sexual contact  900  875  1,007  1,014  926  935  57 (6.3)  46 (5.3)  34 (3.4)  45 (4.4) 42 (4.5) 33 (3.5) 
Injection drug use 2,001 1,981 1,655 1,952 2,015 1,915 18 (0.9) 20 (1.0) 17 (1.0) 27 (1.4) 34 (1.7) 30 (1.6) 
Heterosexual contacta 7,550 7,616 8,089 7,717 7,815 7,381 40 (0.5) 38 (0.5) 56 (0.7) 34 (0.4) 55 (0.7) 46 (0.6) 
Otherb 1,444 1,244 1,341 1,061 1,088 762 12 (0.8) 10 (0.8) 9 (0.7)  — 10 (0.9) 8 (1.0) 
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Table 5.  Reported HIV tests and HIV-positive results, by race/ethnicity and risk category of persons tested, 1999–2004 (continued)
       HIV tests HIV-positive results 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Other race/ethnicity 
Male-to-male sexual contact 191 181 177 168 207 230 11 (5.8) 7 (3.9) 8 (4.5) 8 (4.8) 10 (4.8) 19 (8.3)
 and injection drug use 
Male-to-male sexual contact 1,960 2,116 2,633 2,992 3,442 3,523 96 (4.9) 95 (4.5) 97 (3.7) 123 (4.1) 173 (5.0) 180 (5.1) 
Injection drug use 1,392 1,650 1,741 1,888 2,224 2,370 30 (2.2) 28 (1.7) 23 (1.3) 34 (1.8) 64 (2.9) 80 (3.4) 
Heterosexual contacta 17,678 18,490 20,353 20,840 22,971 24,995 148 (0.8) 155 (0.8) 166 (0.8) 187 (0.9) 228 (1.0) 331 (1.3) 
Otherb 2,566 2,732 3,937 3,843 3,425 3,478 35 (1.4) 40 (1.5) 47 (1.2) 52 (1.4) 39 (1.1) 29 (0.8) 
Race/ethnicity not reported 
Male-to-male sexual contact 115 90 84 111 104 101 7 (6.1)  —  — 8 (7.2) 6 (5.8) 15 (14.9)
 and injection drug use 
Male-to-male sexual contact 962 856 1,091 1,278 1,263 1,774 51 (5.3) 40 (4.7) 67 (6.1) 50 (3.9) 69 (5.5) 109 (6.1) 
Injection drug use 1,337 944 1,139 1,226 1,071 926 36 (2.7) 24 (2.5) 38 (3.3) 31 (2.5) 28 (2.6) 32 (3.5) 
Heterosexual contacta 10,063 8,130 11,694 13,234 11,951 12,632 84 (0.8) 66 (0.8) 179 (1.5) 165 (1.2) 161 (1.3) 124 (1.0) 
Otherb 7,739 7,834 9,301 5,582 5,956 5,260 177 (2.3) 258 (3.3) 170 (1.8) 63 (1.1) 70 (1.2) 109 (2.1) 
Total 1,869,519 1,905,051 1,962,061 1,946,021 1,867,892 1,892,734 27,535 (1.5) 27,067 (1.4) 28,810 (1.5) 28,439 (1.5) 26,984 (1.4) 25,096 (1.3) 
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Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

Dash indicates data not shown because of small cell count.

a Includes persons who had sex with partner at risk, who had a diagnosis of a sexually transmitted disease, who exchanged sex for drugs or money, who had sex while using noninjection drugs, who 
were victims of sexual assault, or whose only risk factor was heterosexual contact. 
b Includes persons who did not report a risk factor, whose record contained no data on risk factors, or who reported other risk factors (i.e., perinatal exposure, hemophilia, receipt of blood 
transfusion, or health care exposure). 
Table 6.  Reported HIV tests and HIV-positive results, by type of testing site and type of test, 1999–2004
       HIV tests HIV-positive results 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Site type 
HIV counseling and 460,027 445,111 435,208 414,149 391,217 383,618 8,914 (1.9) 8,496 (1.9) 8,595 (2.0) 8,784 (2.1) 8,109 (2.1) 6,856 (1.8)
 testing center 
STD clinic 542,404 563,997 590,056 565,270 541,747 576,832 7,119 (1.3) 6,606 (1.2) 6,883 (1.2) 5,759 (1.0) 6,048 (1.1) 5,743 (1.0) 
Drug treatment center 117,671 120,402 123,630 124,477 113,500 114,525 2,187 (1.9) 2,327 (1.9) 2,339 (1.9) 2,225 (1.8) 1,825 (1.6) 1,494 (1.3) 
Family planning clinic 171,597 171,411 175,160 185,002 165,014 161,459 349 (0.2) 357 (0.2) 315 (0.2) 346 (0.2) 278 (0.2) 326 (0.2) 
Prenatal/OB-GYN 146,457 128,778 117,903 106,179 93,953 86,142 917 (0.6) 722 (0.6) 649 (0.6) 486 (0.5) 311 (0.3) 297 (0.3) 
Tuberculosis clinic 16,019 15,083 15,445 14,324 13,301 12,284 255 (1.6) 223 (1.5) 178 (1.2) 178 (1.2) 155 (1.2) 172 (1.4) 
Community health center/ 125,270 128,542 147,120 146,461 150,124 147,913 2,192 (1.7) 2,364 (1.8) 3,391 (2.3) 3,960 (2.7) 3,935 (2.6) 3,535 (2.4)
 public health clinic 
Prison/jail 105,925 116,087 124,496 130,992 111,739 136,054 2,643 (2.5) 2,506 (2.2) 2,669 (2.1) 2,573 (2.0) 1,787 (1.6) 1,966 (1.4) 
Hospital/private medical 16,708 14,390 15,865 18,604 19,477 23,006 422 (2.5) 266 (1.8) 341 (2.1) 555 (3.0) 607 (3.1) 513 (2.2)
   doctor’s office 
Field visit 64,400 112,623 118,299 144,715 127,926 140,555 1,019 (1.6) 1,725 (1.5) 1,848 (1.6) 2,315 (1.6) 2,122 (1.7) 2,575 (1.8) 
Othera 103,041 88,627 98,879 95,848 139,894 110,346 1,518 (1.5) 1,475 (1.7) 1,602 (1.6) 1,258 (1.3) 1,807 (1.3) 1,619 (1.5) 
Test type 
Anonymous 423,653 398,050 383,342 349,048 307,641 265,723 6,589 (1.6) 6,022 (1.5) 5,864 (1.5) 5,328 (1.5) 4,732 (1.5) 3,633 (1.4) 
Confidential 1,420,737 1,493,551 1,565,054 1,584,597 1,541,129 1,611,534 20,692 (1.5) 20,854 (1.4) 22,738 (1.5) 22,916 (1.4) 22,056 (1.4) 21,261 (1.3) 
Not reportedb 25,129 13,450 13,665 12,376 19,122 15,477 254 (1.0) 191 (1.4) 208 (1.5) 195 (1.6) 196 (1.0) 202 (1.3) 
Total 1,869,519 1,905,051 1,962,061 1,946,021 1,867,892 1,892,734 27,535 (1.5) 27,067 (1.4) 28,810 (1.5) 28,439 (1.5) 26,984 (1.4) 25,096 (1.3) 
1
5

 Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

STD, sexually transmitted disease; OB-GYN, obstetrics and gynecology.

a Includes site types not listed and records that did not specify a site type. 
b Includes records without a value for this variable. 
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Table 7.  Reported HIV tests and receipt of HIV results, by characteristics of persons tested and by test result, 1999–2004
 HIV tests             HIV test results received 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Age at test (yrs) 
<5 3,266 3,096 1,230 998 778 902 1,627 (49.8) 1,352 (43.7) 1,000 (81.3) 774 (77.6) 593 (76.2) 729 (80.8)
 5–12 2,942 2,432 2,350 2,072 1,562 1,720 2,011 (68.4) 1,672 (68.8) 1,592 (67.7) 1,405 (67.8) 1,073 (68.7) 1,298 (75.5) 
13–18 156,550 156,189 145,654 141,434 125,995 150,779 101,098 (64.6) 100,583 (64.4) 91,523 (62.8) 88,593 (62.6) 80,213 (63.7) 109,579 (72.7) 
19–24 380,815 397,464 399,931 404,929 382,987 444,522 264,412 (69.4) 272,781 (68.6) 270,521 (67.6) 271,123 (67.0) 260,498 (68.0) 335,011 (75.4) 
25–34 416,537 422,839 414,806 415,085 395,163 446,983 302,464 (72.6) 304,874 (72.1) 296,696 (71.5) 295,729 (71.2) 285,420 (72.2) 350,852 (78.5) 
35–44 289,100 303,998 297,864 294,642 277,938 305,575 215,994 (74.7) 225,413 (74.1) 220,100 (73.9) 217,250 (73.7) 207,411 (74.6) 245,500 (80.3) 
45–54 114,390 127,380 131,800 137,722 137,702 161,248 88,161 (77.1) 96,675 (75.9) 99,774 (75.7) 103,707 (75.3) 104,223 (75.7) 130,667 (81.0) 
55–64 28,417 32,140 33,191 35,771 36,299 43,738 22,400 (78.8) 25,188 (78.4) 25,725 (77.5) 27,690 (77.4) 28,194 (77.7) 36,506 (83.5) 
≥65 9,317 10,685 11,699 11,767 10,946 12,582 7,514 (80.6) 8,498 (79.5) 9,252 (79.1) 9,231 (78.4) 8,588 (78.5) 10,572 (84.0) 
Not reporteda 16,884 16,840 28,079 28,055 21,713 18,487 10,464 (62.0) 11,467 (68.1) 20,640 (73.5) 22,175 (79.0) 17,426 (80.3) 15,104 (81.7) 
Race/ethnicity 
White, not Hispanic 613,529 599,048 567,698 554,721 512,804 579,903 479,572 (78.2) 470,035 (78.5) 437,221 (77.0) 416,713 (75.1) 386,789 (75.4) 475,632 (82.0) 
Black, not Hispanic 444,335 482,870 491,264 492,532 485,734 596,279 271,567 (61.1) 294,446 (61.0) 298,630 (60.8) 304,094 (61.7) 309,285 (63.7) 425,372 (71.3) 
Hispanic 287,872 318,844 333,858 349,428 317,269 324,758 211,789 (73.6) 231,864 (72.7) 246,704 (73.9) 259,427 (74.2) 240,332 (75.8) 264,187 (81.3) 
Asian/Pacific Islander 26,666 26,500 26,968 28,154 27,064 28,253 21,055 (79.0) 20,590 (77.7) 21,078 (78.2) 22,321 (79.3) 21,460 (79.3) 23,547 (83.3) 
American Indian/ 10,185 9,966 10,591 10,676 10,788 10,179 7,586 (74.5) 7,419 (74.4) 7,625 (72.0) 7,679 (71.9) 7,537 (69.9) 7,909 (77.7) 
Alaska Native 
Other 21,137 22,403 24,576 25,245 27,030 32,649 15,790 (74.7) 16,719 (74.6) 18,101 (73.7) 18,729 (74.2) 20,733 (76.7) 26,709 (81.8) 
Not reporteda 14,494 13,432 11,649 11,719 10,394 14,515 8,786 (60.6) 7,430 (55.3) 7,464 (64.1) 8,714 (74.4) 7,503 (72.2) 12,462 (85.9) 
Sex 
Male 701,095 745,629 756,055 762,588 730,435 816,058 517,752 (73.8) 544,555 (73.0) 549,117 (72.6) 554,457 (72.7) 532,744 (72.9) 643,556 (78.9) 
Female 712,134 718,748 704,804 702,486 651,649 762,397 495,405 (69.6) 499,718 (69.5) 483,508 (68.6) 477,611 (68.0) 453,819 (69.6) 585,662 (76.8) 
Not reporteda 4,989 8,686 5,745 7,401 8,999 8,081 2,988 (59.9) 4,230 (48.7) 4,198 (73.1) 5,609 (75.8) 7,076 (78.6) 6,600 (81.7) 
Test result 
Negative 1,387,959 1,442,218 1,432,902 1,435,958 1,358,036 1,543,088 995,952 (71.8) 1,028,274 (71.3) 1,015,690 (70.9) 1,015,405 (70.7) 972,999 (71.6) 1,201,596 (77.9) 
Positive 20,479 20,852 20,500 20,113 18,753 22,491 16,048 (78.4) 16,223 (77.8) 16,679 (81.4) 16,213 (80.6) 15,126 (80.7) 18,935 (84.2) 
Inconclusive 1,762 1,760 2,149 1,937 1,793 8,567 1,231 (69.9) 1,211 (68.8) 1,437 (66.9) 1,321 (68.2) 1,216 (67.8) 8,151 (95.1) 
No result reported 8,018 8,233 11,053 14,467 12,501 12,390 2,914 (36.3) 2,795 (33.9) 3,017 (27.3) 4,738 (32.8) 4,298 (34.4) 7,136 (57.6) 
Total 1,418,218 1,473,063 1,466,604 1,472,475 1,391,083 1,586,536 1,016,145 (71.6) 1,048,503 (71.2) 1,036,823 (70.7) 1,037,677 (70.5) 993,639 (71.4) 1,235,818 (77.9) 
Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

The total number of tests differs from totals in other tables because of missing data on the "receipt of results" variable.

a Includes records without a value for this variable. 
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Table 8.  Reported HIV tests and receipt of HIV results, by race/ethnicity of persons tested and by test result, 1999–2004
 HIV tests             HIV test results received 
1999 2000 2001 2002 2003 2004 1999 2000 2001 2002 2003 2004 
No. No. No. No. No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
White, not Hispanic 
Negative 605,851 591,763 559,722 545,344 504,741 567,680 474,289 (78.3) 464,965 (78.6) 431,671 (77.1) 410,886 (75.3) 381,560 (75.6) 465,816 (82.1) 
Positive 4,699 4,526 4,557 4,549 4,276 5,285 3,809 (81.1) 3,741 (82.7) 3,829 (84.0) 3,799 (83.5) 3,453 (80.8) 4,606 (87.2) 
Othera 2,979 2,759 3,419 4,828 3,787 6,938 1,474 (49.5) 1,329 (48.2) 1,721 (50.3) 2,028 (42.0) 1,776 (46.9) 5,210 (75.1) 
Black, not Hispanic 
Negative 430,911 469,051 475,601 476,135 469,857 577,859 262,507 (60.9) 285,505 (60.9) 289,228 (60.8) 294,570 (61.9) 300,106 (63.9) 411,688 (71.2) 
Positive 10,150 10,257 9,985 9,574 8,856 11,218 7,830 (77.1) 7,789 (75.9) 7,972 (79.8) 7,496 (78.3) 7,023 (79.3) 9,206 (82.1) 
Othera 3,274 3,562 5,678 6,823 7,021 7,202 1,230 (37.6) 1,152 (32.3) 1,430 (25.2) 2,028 (29.7) 2,156 (30.7) 4,478 (62.2) 
Hispanic 
Negative 280,037 310,298 324,938 339,882 309,523 315,244 206,654 (73.8) 226,329 (72.9) 241,242 (74.2) 253,326 (74.5) 235,048 (75.9) 256,389 (81.3) 
Positive 4,781 5,148 5,177 5,222 4,700 4,698 3,864 (80.8) 4,140 (80.4) 4,307 (83.2) 4,295 (82.2) 3,892 (82.8) 4,026 (85.7) 
Othera 3,054 3,398 3,743 4,324 3,046 4,816 1,271 (41.6) 1,395 (41.1) 1,155 (30.9) 1,806 (41.8) 1,392 (45.7) 3,772 (78.3) 
Asian/Pacific Islander 
Negative 26,381 26,254 26,685 27,849 26,722 27,735 20,875 (79.1) 20,412 (77.7) 20,884 (78.3) 22,108 (79.4) 21,203 (79.3) 23,140 (83.4) 
Positive 165 183 196 202 235 224 131 (79.4) 146 (79.8) 152 (77.6) 166 (82.2) 201 (85.5) 178 (79.5) 
Othera 120 63 87 103 107 294 49 (40.8) 32 (50.8) 42 (48.3) 47 (45.6) 56 (52.3) 229 (77.9) 
American Indian/Alaska Native 
Negative 9,977 9,806 10,400 10,471 10,620 9,606 7,456 (74.7) 7,311 (74.6) 7,509 (72.2) 7,530 (71.9) 7,416 (69.8) 7,373 (76.8) 
Positive 122 109 114 111 126 115 94 (77.0) 81 (74.3) 85 (74.6) 90 (81.1) 99 (78.6) 96 (83.5) 
Othera 86 51 77 94 42 458 36 (41.9) 27 (52.9) 31 (40.3) 59 (62.8) 22 (52.4) 440 (96.1) 
Other race/ethnicity 
Negative 20,784 22,047 24,188 24,757 26,413 30,929 15,564 (74.9) 16,454 (74.6) 17,842 (73.8) 18,406 (74.3) 20,309 (76.9) 25,161 (81.4) 
Positive 264 281 275 334 438 613 192 (72.7) 229 (81.5) 213 (77.5) 265 (79.3) 354 (80.8) 513 (83.7) 
Othera 89 75 113 154 179 1,107 34 (38.2) 36 (48.0) 46 (40.7) 58 (37.7) 70 (39.1) 1,035 (93.5) 
Race/ethnicity not reported 
Negative 14,018 12,999 11,368 11,520 10,160 14,035 8,607 (61.4) 7,298 (56.1) 7,314 (64.3) 8,579 (74.5) 7,357 (72.4) 12,029 (85.7) 
Positive 298 348 196 121 122 338 128 (43.0) 97 (27.9) 121 (61.7) 102 (84.3) 104 (85.2) 310 (91.7) 
Othera 178 85 85 78 112 142 51 (28.7) 35 (41.2) 29 (34.1) 33 (42.3) 42 (37.5) 123 (86.6) 
Total 1,418,218 1,473,063 1,466,604 1,472,475 1,391,083 1,586,536 1,016,145 (71.6) 1,048,503 (71.2) 1,036,823 (70.7) 1,037,677 (70.5) 993,639 (71.4) 1,235,818 (77.9) 
Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

The total number of tests differs from totals in other tables because of missing data on the "receipt of results" variable.

a Includes inconclusive test results and tests for which no result was provided.

Table 9.  Test-level data on HIV tests and HIV-positive results, by health department, 1999–2004
       HIV tests HIV-positive results
 1999 2000 2001  2002  2003 2004 1999 2000 2001 2002 2003 2004
 No. No. No.  No.  No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Arizona 18,008 20,121 20,266 21,412 19,429 16,736 351 (1.9) 327 (1.6) 325 (1.6) 347 (1.6) 249 (1.3) 351 (2.1) 
California 141,935 144,141 132,469 126,804 118,907 102,509 1,253 (0.9) 1,240 (0.9) 1,302 (1.0) 1,318 (1.0) 1,325 (1.1) 1,060 (1.0) 
Chicago 17,156 18,326 21,885 21,690 24,034 20,363 203 (1.2) 187 (1.0) 207 (0.9) 209 (1.0) 231 (1.0) 195 (1.0) 
Colorado 23,774 21,029 22,623 22,703 16,963 16,262 364 (1.5) 125 (0.6) 158 (0.7) 197 (0.9) 136 (0.8) 57 (0.4) 
Connecticut 21,072 18,730 18,133 17,398 16,545 18,073 298 (1.4) 233 (1.2) 250 (1.4) 188 (1.1) 165 (1.0) 164 (0.9) 
Delaware 9,159 10,112 10,165 8,181 10,851 13,093 89 (1.0) 116 (1.1) 113 (1.1) 81 (1.0) 139 (1.3) 147 (1.1) 
District of Columbia 15,617 16,752 18,548 18,544 17,068 18,902 287 (1.8) 256 (1.5) 275 (1.5) 318 (1.7) 272 (1.6) 323 (1.7) 
Florida 221,694 232,352 260,904 286,650 293,444 272,867 4,614 (2.1) 4,987 (2.1) 6,045 (2.3) 6,316 (2.2) 6,228 (2.1) 5,252 (1.9) 
Georgia 75,757 76,908 82,704 87,191 86,677 99,790 1,718 (2.3) 1,726 (2.2) 1,956 (2.4) 1,695 (1.9) 1,708 (2.0) 1,628 (1.6) 
Houston 20,427 19,987 19,975 22,521 17,321 23,677 581 (2.8) 407 (2.0) 267 (1.3) 511 (2.3) 463 (2.7) 542 (2.3) 
Idaho 13,171 12,082 8,734 2,254 2,997 2,152 51 (0.4) 33 (0.3) 25 (0.3) 7 (0.3) 15 (0.5) 7 (0.3) 
Illinois 47,484 46,141 45,203 43,488 44,157 47,052 344 (0.7) 431 (0.9) 431 (1.0) 358 (0.8) 338 (0.8) 345 (0.7) 
Indiana 25,049 23,366 28,156 22,695 19,316 34,002 239 (1.0) 250 (1.1) 286 (1.0) 259 (1.1) 106 (0.5) 266 (0.8) 
Kentucky 18,385 19,344 17,828 17,389 15,859 14,121 124 (0.7) 134 (0.7) 97 (0.5) 117 (0.7) 103 (0.6) 60 (0.4) 
Los Angeles 75,005 78,467 75,382 70,225 72,190 52,682 1,169 (1.6) 1,133 (1.4) 1,116 (1.5) 1,081 (1.5) 1,185 (1.6) 721 (1.4) 
Louisiana 58,280 60,397 50,082 52,056 55,130 65,285 652 (1.1) 618 (1.0) 577 (1.2) 606 (1.2) 569 (1.0) 661 (1.0) 
Maine ND 2,233 2,306 2,487 2,789 2,877  ND 8 (0.4) 14 (0.6) 9 (0.4) 24 (0.9) 19 (0.7) 
Maryland 66,465 66,691 87,106 72,331 60,339 84,351 1,277 (1.9) 1,216 (1.8) 1,610 (1.8) 1,270 (1.8) 1,245 (2.1) 1,438 (1.7) 
Massachusetts 43,559 45,247 50,772 46,087 42,435 46,242 556 (1.3) 495 (1.1) 514 (1.0) 620 (1.3) 449 (1.1) 457 (1.0) 
Michigan 61,432 58,485 59,104 59,472 36,294 44,575 514 (0.8) 459 (0.8) 550 (0.9) 611 (1.0) 322 (0.9) 402 (0.9) 
Minnesota 7,794 8,775 9,448 10,540 9,619 9,781 65 (0.8) 105 (1.2) 65 (0.7) 83 (0.8) 116 (1.2) 123 (1.3) 
Missouri 31,637 39,594 34,599 24,343 24,305 17,601 233 (0.7) 254 (0.6) 238 (0.7) 160 (0.7) 176 (0.7) 116 (0.7) 
Montana 4,355 3,546 3,626 3,162 4,437 4,916 11 (0.3) 9 (0.3) 11 (0.3) 14 (0.4) 23 (0.5) 16 (0.3) 
Nebraska 5,817 5,921 5,816 6,407 7,396 7,678 52 (0.9) 24 (0.4) 50 (0.9) 44 (0.7) 34 (0.5) 40 (0.5) 
Nevada 25,645 23,912 26,314 29,201 21,446 21,185 197 (0.8) 207 (0.9) 223 (0.8) 263 (0.9) 297 (1.4) 292 (1.4) 
New Jersey 59,444 57,908 63,576 66,639 66,187 67,921 1,823 (3.1) 1,459 (2.5) 1,423 (2.2) 1,332 (2.0) 1,124 (1.7) 1,116 (1.6) 
New Mexico 11,905 5,004 5,912 7,761 5,565 7,905 35 (0.3) 24 (0.5) 36 (0.6) 39 (0.5) 38 (0.7) 54 (0.7) 
New York 109,555 95,348 91,529 93,581 92,094 96,632 1,826 (1.7) 1,663 (1.7) 1,619 (1.8) 1,824 (1.9) 1,669 (1.8) 1,743 (1.8) 
New York City 31,425 32,620 33,127 33,408 33,386 33,706 805 (2.6) 644 (2.0) 593 (1.8) 581 (1.7) 553 (1.7) 483 (1.4) 
North Carolina 102,432 105,790 119,009 105,700 107,068 119,073 697 (0.7) 739 (0.7) 886 (0.7) 754 (0.7) 743 (0.7) 716 (0.6) 
North Dakota  ND ND ND  ND 2,149 2,558 ND  ND  ND  ND 6 (0.3)  — 
Ohio 42,815 41,424 42,627 39,934 44,285 47,841 359 (0.8) 383 (0.9) 407 (1.0) 410 (1.0) 430 (1.0) 477 (1.0) 
Oklahoma 11,366 8,338 6,927 6,992 7,234 6,987 171 (1.5) 139 (1.7) 173 (2.5) 132 (1.9) 149 (2.1) 112 (1.6) 
Oregon 22,051 21,475 21,342 21,691 20,874 19,990 182 (0.8) 201 (0.9) 212 (1.0) 213 (1.0) 221 (1.1) 194 (1.0) 
Pennsylvania 51,409 45,048 42,642 49,544 54,845 58,453 625 (1.2) 355 (0.8) 402 (0.9) 469 (0.9) 443 (0.8) 432 (0.7) 
Philadelphia 9,384 27,165 28,477 29,655 31,340 32,916 290 (3.1) 712 (2.6) 739 (2.6) 687 (2.3) 666 (2.1) 648 (2.0) 
Puerto Rico 43,319 57,026 64,792 72,824 64,153 41,763 1,486 (3.4) 1,694 (3.0) 1,766 (2.7) 1,656 (2.3) 1,362 (2.1) 842 (2.0) 
Rhode Island 2,659 3,088 3,075 3,017 2,814 3,147 21 (0.8) 20 (0.6) 18 (0.6) 19 (0.6) 24 (0.9) 24 (0.8) 
San Francisco 22,354 25,426 25,006 19,097 20,378 21,913 716 (3.2) 796 (3.1) 748 (3.0) 699 (3.7) 736 (3.6) 729 (3.3) 
South Carolina 38,392 39,505 43,648 46,373 45,109 48,900 911 (2.4) 824 (2.1) 848 (1.9) 811 (1.7) 777 (1.7) 762 (1.6) 
Tennessee 39,285 41,316 41,959 42,152 46,499 47,536 382 (1.0) 476 (1.2) 472 (1.1) 340 (0.8) 445 (1.0) 505 (1.1) 
Texas 100,221 102,449 92,063 86,694 56,377 49,864 1,252 (1.2) 1,220 (1.2) 1,044 (1.1) 1,026 (1.2) 822 (1.5) 717 (1.4) 
U.S. Virgin Islands 592 1,426 1,290 1,436 1,613 2,626  — 25 (1.8) 23 (1.8) 24 (1.7) 14 (0.9) 31 (1.2) 
Utah 6,411 6,409 5,913 6,004 6,883 8,089 33 (0.5) 30 (0.5) 34 (0.6) 47 (0.8) 60 (0.9) 72 (0.9) 
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Table 9.  Test-level data on HIV tests and HIV-positive results, by health department, 1999–2004 (continued)
       HIV tests HIV-positive results
 1999 2000 2001  2002  2003 2004 1999 2000 2001 2002 2003 2004
 No. No. No.  No.  No. No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Vermont 1,084 1,552 2,050 2,446 2,453 2,778 9 (0.8)  —  — 22 (0.9) 11 (0.4)  — 
Virginia 75,013 75,702 78,125 79,076 80,756 79,141 460 (0.6) 437 (0.6) 435 (0.6) 453 (0.6) 534 (0.7) 517 (0.7) 
Washingtona 15,324 15,215 14,489 13,340 12,099 11,944 70 (0.5) 82 (0.5) 87 (0.6) 71 (0.5) 90 (0.7) 92 (0.8) 
Wisconsin 18,324 19,040 18,772 19,423 19,659 19,477 134 (0.7) 153 (0.8) 128 (0.7) 127 (0.7) 141 (0.7) 130 (0.7) 
Wyoming 6,078 4,118 3,563 4,003 4,124 4,802 6 (0.1) 11 (0.3) 12 (0.3) 21 (0.5) 8 (0.2) 18 (0.4) 
Total 1,869,519 1,905,051 1,962,061 1,946,021 1,867,892 1,892,734 27,535 (1.5) 27,067 (1.4) 28,810 (1.5) 28,439 (1.5) 26,984 (1.4) 25,096 (1.3) 
Note. Includes areas that report test-level data to CDC. See Table 1 and Technical Notes for details. Since 1999, the following areas have had test-level reporting: Arizona, California, Chicago, Colorado,

Connecticut, Delaware, District of Columbia, Florida, Georgia, Houston, Idaho, Illinois, Indiana, Kentucky, Los Angeles, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,

Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, New York City, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Philadelphia, Puerto Rico, Rhode Island, San Francisco,

South Carolina, Tennessee, Texas, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming. Maine began test-level reporting in 2000 and North Dakota in 2003.

Data for Mississippi are not included because of concerns about data reliability.

To protect confidentiality, minor adjustments have been made to some of the cells.

The names of the 6 municipalities (Chicago, Houston, Los Angeles, New York City, Philadelphia, and San Francisco) are incorporated in the alphabetical listing.

Dash indicates data not shown because of small cell count; ND, no data (areas reported aggregate-level, not test-level, data).

a Excludes King County, which reports aggregate-level data. 
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Technical Notes

Overview of the HIV Counseling 
and Testing System 
Counseling and testing data are collected to 
facilitate program monitoring and evaluation at the 
local, state, and national levels. These data include 
information that would typically be gathered in the 
process of providing testing services (e.g., age and 
risk factors). To standardize the collection of 
counseling and testing data, CDC provides health 
departments with variables, definitions, and coding 
conventions. CDC requires the health departments 
to submit quarterly reports on the HIV counseling 
and testing services supported by CDC. 
Health departments that report test-level data 
(Table 1) submit data to CDC electronically, using 
a specified file structure. CDC has assisted health 
departments in collecting counseling and testing 
test-level data by making available standardized 
machine-readable forms (scan forms) and scan 
software. Other health departments have devel­
oped their own data collection systems and may 
use one of the following: scanning technology 
similar to the CDC system; a system wherein the 
data are hand keyed; or, more recently, a Web-
based system. 
Health departments that submit aggregate-level 
data (Table 1) complete a standardized set of 
tables, which include summary counts of testing 
activities by certain characteristics of persons 
(e.g., the number of tests administered to black 
females). Aggregate-level data are not presented in 
Tables 3–9 of this report because of (a) differences 
in variables used to report test- and aggregate-level 
data, (b) inability to manipulate aggregate-level 
data to cross-tabulate two or more variables, and 
(c) limited ability to evaluate the impact of missing
data on estimates. 
Limitations of the Collection 
and Reporting of Counseling 
and Testing Data 
Although service providers and health depart­
ments make considerable efforts to collect and 
report the data in a consistent manner, there are 
limitations in these processes. Data errors may 
occur in any large-scale data collection effort and 
may include errors in coding and data entry, 
conversion, and import. Limitations specific to the 
collection of counseling and testing data result 
from the complexity and sensitive nature of an 
HIV counseling and testing session and variations 
in the way service providers obtain data. People’s 
reluctance to discuss personal and highly sensitive 
topics and variation in the ability of service pro­
viders to elicit this information may result in 
misidentification of the risk factors of the person 
being tested. For example, an experienced counse­
lor may be more effective than a new counselor in 
identifying behavioral risks, which may affect the 
risk factor data recorded for that person. 
Variations in data collection systems used by 
health departments may also limit the comparabil­
ity of the data. Although standardized variables 
and definitions are provided, health departments 
may vary in how they apply these data elements. 
Differences in the wording of a particular item can 
undermine comparability. CDC, for example, 
defines “since 1978” as the recall period for 
behaviors that may place a person at risk for HIV; 
health departments may use a different recall 
period, such as “in the past 2 years” or “since your 
last HIV test,” in their data collection systems. 
Accurately estimating the receipt of HIV test 
results is complicated by differences in data collec­
tion systems (e.g., ease of update in a scan- vs. a 
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Web-based system), management processes (e.g., 
length of time a form is held before data 
processing), and type of test (e.g., anonymous 
vs. confidential). 
Data Review Procedures 
CDC and health departments follow quality 
control procedures to help minimize error. Coun­
seling and testing data are reviewed at various 
stages in the processes of data collection, submis­
sion, and analysis. The CDC-supported scanning 
system performs several consistency checks on the 
data, for example, to identify whether a response 
falls outside a predefined range of plausible 
values. Other data collection systems used by the 
health departments have similar checks to assist in 
validating data before submission to CDC. 
Although health departments are often in the 
best position to assess the quality of counseling 
and testing data, CDC also conducts reviews to 
identify possible problems related to data conver­
sion or transmission. CDC tabulates data for each 
health department quarterly and annually and 
returns them to health departments for validation, 
correction, and clarification of any unusual 
changes (e.g., a pronounced change in testing for a 
particular racial/ethnic group or age category). In 
addition, in preparation for this report, CDC 
created summary tables on key report variables for 
1998 through 2003 for each health department 
reporting test-level data. This provided health 
departments the opportunity to validate any appre­
ciable changes in test statistics over time (e.g., an 
increase of 25% or more in HIV testing in prison 
settings) and explain these shifts. Health depart­
ments’ explanations for the shifts focused on 
program changes, community trends, and data 
collection. For example, the large change in the 
number of HIV tests reported by Philadelphia 
between 1999 (9,384) and 2000 (27,165) appears 
to have been caused by some providers in Phila­
delphia not submitting complete data to the health 
department in Philadelphia in 1999 (Table 9). The 
Philadelphia health department indicated that in 
1999 the true count of HIV tests should be 
approximately 23,000. Presumably, there was 
a corresponding change in the number of HIV-
positive test results in 1999. 
During the review of the data, an anomaly was 
discovered in Mississippi’s data. Specifically, from 
2001 through 2004, Mississippi reported an unre­
alistically high number of tests given to men who 
reported having male-to-male sexual contact. 
Mississippi was not able to identify the source of 
this anomaly. Because of the magnitude of this 
anomaly (e.g., in 2000, Mississippi reported 999 
tests for men who reported having male-to-male 
sexual contact, whereas in 2001, Mississippi 
reported 18,402 tests for the same risk category), 
CDC was unable to include Mississippi’s data in 
this report. 
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Analysis Notes

Refer to the Appendix for the set of variables 
collected and reported to CDC by those health 
departments who reported test-level data. Not 
all of the variables on the form were used in 
this report. Below are details on how some of 
the variables were calculated and presented in 
this report. 
Missing Data 
Some records*  in the counseling and testing 
data were missing information on certain variables. 
Most variables with missing data were included in 
the “not reported” category in the tables. However, 
the “site type,” “test result this visit,” “posttest 
counseled,” and risk factor variables were treated 
as follows. 
•	 If “site type” was missing data, the response was 
included in the “other” category in the tables. 
•	 If “test result this visit” was missing data, the 
entire record was excluded from all tables in this 
report. For quality assurance purposes, CDC 
monitored the test result data and consulted with 
the health department if an unusually large 
percentage of records were missing data for 
this variable. 
•	 If “posttest counseled” was missing data, the 
entire record was excluded from tables showing 
data on receipt of results (Tables 7 and 8) but 
was included in tables reporting the number of 
tests (e.g., Table 3). Therefore, the total numbers 
of HIV tests shown in Tables 7 and 8 differ from 
those shown in Table 3. 
•	 If no risk factors were reported, the response 
was included in the “other” category in the 
tables that reported risk categories. 
Calculation of Percentage of HIV 
Test Results That Were Positive 
This variable was calculated as the number 
of HIV tests with a positive result divided by the 
total number of HIV tests for which a value was 
reported (i.e., “positive,” “negative,” “inconclu­
sive,” or “no result”). 
Use of the Posttest Counseling 
Variable 
The 1999 through 2004 counseling and testing 
data do not contain a specific variable for receipt 
of an HIV test result. In this report, receipt of 
posttest counseling is used as a proxy for receipt 
of an HIV test result. 
Race/Ethnicity 
In the Federal Register for October 30, 1997, 
the Office of Management and Budget (OMB) 
announced the Revisions to the Standards for the 
Classification of Federal Data on Race and 
Ethnicity [1]. These revisions reflected a change 
in federal policy regarding the collection of 
data on race and ethnicity; implementation by 
January 1, 2003, was mandated. At a minimum, 
data for the following race categories should 
be collected: 
•	 American Indian or Alaska Native 
•	 Asian 
•	 black or African American 
•	 Native Hawaiian or Other Pacific Islander 
•	 white 
*In this dataset, a record refers to the set of information that is collected about an HIV test and sent to CDC. 
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Additionally, systems must be able to retain 
information when multiple racial categories are 
reported. Two ethnicity categories should be 
collected regardless of race: 
•	 Hispanic 
•	 not Hispanic 
The 1999–2004 data in this report were 
collected by using the race/ethnicity categories 
approved under the previous OMB standards. 
Therefore, the tables do not reflect the new 
categories. Future collections of counseling 
and testing data will comply with the OMB’s 
revised standards. 
Risk Factor Categorization 
The 3 steps by which the reported risk factors 
were categorized to create the risk categories used 
in this report are described in the following text 
and boxes. 
Step 1: Reported Risk Factors 
The counselor collects risk factor information 
from each person tested. More than 1 risk factor 
may be reported for each person. Box 1 lists these 
risk factors with definitions. 
Step 2: Risk Factor Category Assigned 
by Hierarchy 
Using the combination of a person’s reported 
risk factor(s) (see Box 1) and the person’s sex (i.e., 
male or female), CDC assigns each person tested 
to a risk factor category. These categories are 
ordered hierarchically based on the presumed 
likelihood of HIV transmission. This hierarchy is 
based on the HIV transmission hierarchy used in 
CDC HIV/AIDS surveillance. A person is classi­
fied into a risk category on the basis of the risk 
factor(s) most likely to have been responsible for 
transmission. Persons with more than one reported 
risk factor are classified into the risk factor 
category listed first in the hierarchy (see step 2 in 
Box 2 for the order of risk categories in this hier­
archy; categories are ordered from the most likely 
route of transmission to the least likely route of 
transmission). For example, a male who reports 
the following risk factors—sex with male, STD 
diagnosis, and sex with female—would be 
assigned to the risk factor category “male-to-male 
sexual contact.” The exception is men who report 
sexual contact with other men and injection drug 
use, for whom a separate risk category exists 
(i.e., “male-to-male sexual contact and injection 
drug use”). 
Step 3: Risk Categories Used in This Report 
For this report, the 15 risk factor categories 
were further collapsed into 1 of 5 risk categories. 
Box 2 further illustrates the process used for 
deriving the risk categories in this report from the 
risk factors recorded at the time of the counseling 
and testing session. The second and third columns 
show the relationship between the risk factor 
categories and the risk categories used in the tables 
and figures of this report. The numbers in paren­
theses in the third column correspond to the 
numbers listed in the second column. 
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Box 1. Definitions of risk factors reported by person tested 
Risk Factor Definition 
(Persons reported whether they had engaged in any of the risk behaviors 
listed below since 1978.) 
Sex with male Had sex with a male. 
Sex with female Had sex with a female. 
Injection drug use Self-injected or received an injection of a nonprescription drug or substance; 
includes injection routes other than intravenous. 
Sex while under the influence of Engaged in sexual activities while under the influence of noninjection drugs, 
noninjection drugs or alcohol such as crack cocaine, or under the influence of alcohol. 
Exchange of sex for drugs/money Exchanged sex for drugs or money. 
STD diagnosis Received an STD diagnosis since 1978. 
Sex with injection drug user Had sex with an injection drug user (includes persons who injected through 
routes other than intravenous). 
Sex with man who had sex with a man Had sex with a man who had had sex with a man. 
Sex with person with HIV/AIDS Had sex with a person who had HIV infection or AIDS. 
Sex with person with other HIV/AIDS Had sex with a person who had another risk factor not listed above 
risk factor (e.g., a person who had hemophilia or who had received a transfusion of 
blood or blood products). 
Child of woman with HIV/AIDS Had mother with HIV infection or AIDS; child is younger than 13 years. 
Hemophiliac/recipient of blood or Had a hereditary bleeding disorder requiring therapy with clotting factor or 
blood products other blood products or had an injection of whole blood or blood product 
(other than immune globulin preparations) directly into the blood stream 
during 1978–1985. 
Health care exposure Exposed to HIV in a health care setting (patient or health care worker). 
Victim of sexual assault Exposed to HIV as a result of a sexual assault (adult or child). 
No acknowledged risk Had unknown risk exposure. 
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Box 2. Process used to categorize reported risk factors 
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Step 1  
Risk Factors Reported by 
Person Tested 
The counse or se ects each risk 
factor reported. More than 1 risk 
factor may be se ected. 
Step 2 
Risk Factor Category Assigned 
through a Hierarchy 
es each person nto a risk 
factor category by us ng a 
comb on of the reported risk 
factor(s) (see step 1) and the person’s 
sex .e., male or female . This 
classification is based on the 
presumed hierarchy of HIV 
transm
Step 3 
Risk Categories Used in This Report 
The codes from the hierarchy are 
reported as 1 of 5 risk categories, as 
ndicated below. 
Sex w th male 
Sex w th female 
In ect on drug use 
Sex wh e under the inf uence of
 noninject on drugs 
Exchange of sex for 
 drugs/money 
STD diagnos
Sex w th ect on drug user  
Sex w th man who had sex w th
  a man 
Sex w th person w th HIV/AIDS 
Sex w th person w th other 
  HIV AIDS r sk factor 
Ch d o  woman with H
Hemophi ac rec ent of
 blood or b ood products 
Health care exposure 
m of sexual assault 
No acknow edged risk 
01 = Ma e-to-ma e sexual contact and 
ect on drug use 
02 = Ma e-to-ma e sexual contact 
03 = In ect on drug use 
04 = Sex w th partner at risk 
05 = Perinata  exposure 
06 = STD diagnosis 
07 = Exchange of sex for 
 drugs/money 
08 = Sex wh e under the inf uence of
 noninject on drugs 
09 = Hemophilia receipt of blood or
 blood products 
m of sexual assault 
11 = Health care exposure 
12 = No acknow edged risk 
13 = Heterosexual contact  no other 
sk 
14 = Other 
15 = Not spec
Ma e-to-ma e sexual contact and
ect on drug use (01) 
Ma e-to-ma e sexual contact (02
In ect on drug use (03) 
Heterosexual contact 
Sex w th partner at risk (04) 
STD diagnos
Exchange of sex for  
 drugs/money (07) 
Sex wh e under the inf uence of 
noninject on drugs (08) 
m of sexual assault (10) 
Heterosexual contact
 no other risk (13) 
Other 
Perinatal exposure (05) 
Hemophi a/rece pt of blood or blood 
products (09) 
th care exposure (11) 
No acknow edged risk (12) 
 Other (14) 
 Not spec ed (15) 
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Appendix

From 1999 through 2004, some health depart- all health departments used this form to collect 
ments used the CDC-provided form reproduced on data, all health departments that reported test-
the next page to collect data from persons during level data submitted the data elements included 
the counseling and testing session. Although not on the form. 
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